Drug interaction lawsuits are legal claims brought by individuals or groups harmed by adverse reactions resulting from the simultaneous use of multiple medications or supplements that dangerously interact with each other. These lawsuits typically target pharmaceutical companies, pharmacy chains, healthcare providers, or technology companies that failed to warn consumers about dangerous drug combinations or actively provided negligent advice about drug safety. The most prominent recent case involves parents from Texas suing OpenAI after their 19-year-old son Sam Nelson died in 2025 from a drug overdose—ChatGPT had incorrectly told him it was safe to combine kratom, a botanical supplement, with Xanax, an anti-anxiety medication prescribed by his doctor, a combination that caused fatal respiratory depression. Drug interactions occur when two or more substances affect each other’s behavior in the body, potentially increasing toxicity, reducing effectiveness, or causing entirely new harmful effects. Some drug combinations are well-documented dangers—combining certain antidepressants with over-the-counter pain relievers can cause life-threatening bleeding; mixing alcohol with opioids can suppress breathing fatally.
When someone is harmed because a pharmacist, doctor, or AI system failed to identify or warn about these interactions, it creates legal liability. What distinguishes drug interaction lawsuits from simple medical malpractice is that they often involve systemic failures—a pharmacy’s outdated interaction-checking software, a pharmaceutical company’s insufficient warning label, or an AI company’s lack of safety guardrails. The liability landscape for drug interactions has expanded significantly in recent years. Historically, the responsibility fell primarily on pharmacists to screen prescriptions for dangerous combinations before dispensing medications. Today, lawsuits also target the artificial intelligence systems that consumers increasingly consult for health advice, and they target pharmaceutical manufacturers whose inadequate labeling contributed to the harm. These cases raise fundamental questions about who bears responsibility when modern technology intersects with medical safety.
Table of Contents
- HOW DO DRUG INTERACTIONS CAUSE HARM AND CREATE LEGAL LIABILITY?
- PHARMACY ERRORS AND THE DUTY TO CHECK DRUG INTERACTIONS
- THE OPENAI CHATGPT DRUG OVERDOSE LAWSUIT—A WATERSHED MOMENT
- WHO IS RESPONSIBLE FOR DRUG INTERACTION HARM?
- BROADER PHARMACEUTICAL SETTLEMENTS AND DRUG PRICING LITIGATION
- PHARMACEUTICAL COMPANY RESPONSIBILITY AND WARNING LABELS
- THE FUTURE OF DRUG INTERACTION LIABILITY IN THE AI AGE
- Conclusion
- Frequently Asked Questions
HOW DO DRUG INTERACTIONS CAUSE HARM AND CREATE LEGAL LIABILITY?
Drug interactions cause harm through several mechanisms. Some interactions increase the concentration of a drug in the bloodstream to toxic levels—grapefruit juice, for example, can prevent the body from processing certain cholesterol medications safely, leading to muscle damage and kidney failure in severe cases. Other interactions reduce a drug’s effectiveness entirely, leaving patients without necessary treatment. Still others create new and unexpected side effects. When a Walgreens pharmacist dispenses a prescription for a drug that interacts dangerously with medications the patient is already taking, that failure constitutes negligence if the pharmacy’s system should have flagged the interaction. Legal liability arises when someone in a position of responsibility—a pharmacist, a pharmaceutical company, or increasingly, an AI system—fails to identify a dangerous interaction that a reasonable professional should have caught.
In the OpenAI case, for example, the lawsuit alleges that ChatGPT should never have provided medical advice about combining substances without a clear disclaimer that it was not a substitute for professional medical judgment and that users should consult their actual doctor. The fact that Sam Nelson acted on ChatGPT’s advice and died as a result gives his parents legal grounds to claim OpenAI bears responsibility for the harm. The severity of drug interactions varies enormously. Some produce mild side effects like nausea or headaches that resolve quickly. Others, like the kratom-Xanax combination that killed Sam Nelson, can prove fatal within hours. This variation in severity affects both the moral case for a lawsuit and the potential damages awarded. A jury is far more likely to award substantial damages in a wrongful death case than in a case involving temporary digestive upset, which explains why the most prominent drug interaction lawsuits often involve serious injuries or death.
PHARMACY ERRORS AND THE DUTY TO CHECK DRUG INTERACTIONS
Pharmacists have a legal and ethical duty to review every prescription for potential interactions before dispensing medications to patients. This responsibility exists because pharmacists are trained, licensed professionals with access to detailed drug databases—they are uniquely positioned to catch dangerous combinations that patients or even prescribing doctors might miss. When a pharmacy fails in this duty, it exposes itself to liability. Walgreens, CVS, Rite Aid, and independent pharmacies have all faced litigation over pharmacy errors, including cases where patients were dispensed wrong medications, wrong dosages, or medications that interacted dangerously with drugs listed in the patient’s profile. The reality of modern pharmacy practice introduces a significant limitation: pharmacies operate under intense time pressure. The average pharmacist fills over 300 prescriptions per day while managing staffing shortages, insurance verification issues, and customer service demands.
While this workload pressure does not excuse genuine negligence, it does mean that some dangerous interactions slip through despite pharmacists’ best efforts, particularly when patients use multiple pharmacies or fail to disclose all medications they are taking. A patient who visits a Walgreens for anxiety medication but never mentions the supplements they buy at a health food store creates a gap in the pharmacy’s knowledge that no system can fill. Pharmacy errors have spawned an entire category of drug interaction lawsuits. Some cases involve prescribing errors that reach the pharmacy—a doctor writes a dosage that is dangerously high when combined with another drug the patient is on, and the pharmacist should have flagged it. Other cases involve genuine pharmacy negligence, such as when a pharmacy’s interaction-checking software is outdated or the pharmacist simply fails to review the patient’s medication profile carefully. Pursuing a pharmacy error case requires documentation of the prescription, evidence of the interaction, and proof that a reasonable pharmacist would have caught the problem.
THE OPENAI CHATGPT DRUG OVERDOSE LAWSUIT—A WATERSHED MOMENT
In 2025, Leila Turner-Scott and Angus Scott, parents from Texas, filed a groundbreaking lawsuit in California state court against OpenAI after their 19-year-old son Sam Nelson died from a drug overdose. According to the case details reported by CBS News, Sam consulted ChatGPT about combining kratom, a plant-based supplement popular in the United States, with Xanax, a prescription anti-anxiety medication. ChatGPT incorrectly assured him that the combination was safe. Sam took both substances and suffered fatal respiratory depression—a direct result of the dangerous drug interaction. This case represents a watershed moment in drug interaction litigation because it holds an artificial intelligence company responsible for medical advice that proved catastrophically wrong. OpenAI did not manufacture either kratom or Xanax.
OpenAI is not a pharmacy or a healthcare provider. Yet the lawsuit claims OpenAI bears liability for the consequences of ChatGPT’s negligent advice. The case forces courts and juries to grapple with novel questions: What duty do AI companies owe users who ask for health advice? Should ChatGPT carry the same liability as a pharmacist or doctor if it provides dangerous medical information? What role do consumer expectations play—do people reasonably expect ChatGPT to give accurate medical guidance, or should they know better than to rely on it for life-or-death decisions? The outcome of the OpenAI case will likely influence how courts approach AI liability in drug-related contexts going forward. If the Texas parents prevail, it could establish that AI companies must implement stronger safeguards against providing dangerous medical advice. It could trigger lawsuits against other AI companies offering health guidance. Conversely, if the court finds that OpenAI bears no liability because users should not rely on ChatGPT for medical guidance, it would set a different precedent that limits tech company responsibility. Either way, the case underscores a critical limitation of AI systems: they can sound confident and authoritative while providing completely false information, a phenomenon researchers call “hallucination.”.
WHO IS RESPONSIBLE FOR DRUG INTERACTION HARM?
Responsibility for drug interaction harm can rest with multiple parties, depending on the circumstances. A prescribing doctor bears responsibility if they write a prescription without reviewing the patient’s full medication profile and knowing about dangerous interactions their new prescription would create with existing medications. A pharmacy bears responsibility if its interaction-checking system fails to flag a known dangerous combination. A pharmaceutical company bears responsibility if it fails to include adequate warnings on packaging or in prescribing information about known interactions, particularly if the company knew about the interaction but chose not to disclose it prominently. An AI system bears responsibility if it provides medical advice that directly contradicts established drug safety information. Determining responsibility often requires expertise in both medicine and law. An expert pharmacist can testify that a particular interaction was well-known in the pharmaceutical community and that a competent pharmacist should have flagged it. A medical expert can testify about the causal link between the interaction and the patient’s harm.
An engineer or AI safety expert can testify about what safeguards ChatGPT should have included to prevent dangerous medical misinformation. The more actors involved in the chain leading to harm, the more complex the responsibility analysis becomes. In the OpenAI case, for example, one could argue that both the prescribing doctor (who prescribed Xanax without knowing Sam was taking kratom) and OpenAI (which provided dangerous drug advice) bear some responsibility. A crucial distinction exists between companies that actively cause harm and companies that fail to prevent harm. OpenAI actively caused harm by providing false information that Sam Nelson acted on and died from. Walgreens causes harm when it dispenses a dangerous combination despite having the information needed to prevent it. Express Scripts (a pharmacy benefits manager) caused harm in a different way—not by any individual drug interaction, but by systematically overcharging patients for drugs in ways that pushed them toward cheaper, lower-quality generics or toward forgoing medication entirely. All three scenarios can generate lawsuits, but they involve different legal theories and different defendants.
BROADER PHARMACEUTICAL SETTLEMENTS AND DRUG PRICING LITIGATION
While specific drug interaction cases have proliferated, the pharmaceutical and pharmacy industry faces broader litigation over drug pricing and access. In 2026, 48 states and territories reached a $17.85 million settlement with Lannett Company and Bausch Health for artificially inflating generic drug prices. Some patients were charged 10 or more times the legitimate price for essential generic medications. This price-fixing scandal did not directly involve drug interactions, but it created systemic harm by making essential medications unaffordable for millions of patients, which could indirectly contribute to drug interaction injuries—patients who cannot afford their prescribed medications might seek cheaper alternatives they find online, purchased without pharmaceutical oversight, creating unknown interaction risks. The FTC secured a landmark settlement with Express Scripts in February 2026, expected to reduce out-of-pocket drug costs by up to $7 billion over the next 10 years.
This settlement targeted the pharmacy benefits manager (PBM) system, which acts as a middleman between insurers, pharmacies, and drug manufacturers, often inflating prices in ways that harm consumers. Like the generic drug price-fixing case, the Express Scripts settlement does not directly address drug interactions, but it addresses the financial barriers that prevent patients from taking their medications safely. A patient who cannot afford all the medications their doctor prescribed might skip doses or stop taking a medication entirely, potentially creating new interaction risks with whatever they do take. These broader settlements reveal an important limitation of drug interaction lawsuit strategy: individual cases can address individual tragedies, but they do not solve systemic problems. If millions of patients cannot afford their medications due to price-fixing or PBM schemes, then addressing individual drug interaction injuries through lawsuits is treating symptoms while the underlying disease—pharmaceutical industry dysfunction—persists. The $7 billion expected savings from the Express Scripts settlement could theoretically prevent countless drug interaction injuries by making all prescribed medications affordable to patients who need them, a public health outcome that no individual lawsuit can achieve.
PHARMACEUTICAL COMPANY RESPONSIBILITY AND WARNING LABELS
Pharmaceutical manufacturers bear legal responsibility when they fail to warn patients and healthcare providers about known dangerous drug interactions. If a pharmaceutical company knows that Drug A interacts dangerously with Drug B but fails to include this information in the prescribing information, package insert, or warning label, it can be held liable if a patient is harmed by the interaction. This principle extends to supplements and over-the-counter drugs as well. For example, if a supplement manufacturer sells a product without warning that it interacts dangerously with common prescription medications, patients harmed by that interaction might have a claim against the supplement company. The challenge is that determining what warnings are sufficient is complex. A package insert cannot list every possible interaction—some drugs interact with hundreds of other substances.
Manufacturers must make judgment calls about which interactions are serious enough to warrant prominent warnings, which should be mentioned in smaller print, and which are so rare or well-known that they can be omitted. A lawyer challenging a warning label would argue that a particular interaction was foreseeable, well-known in the medical community, and serious enough that reasonable drug manufacturers should have included it. The drug company would argue that the interaction was too rare, too well-known to require reiteration, or that the burden of listing every interaction would make warning labels incomprehensible. In the OpenAI case, the question of responsibility for pharmaceutical companies does not directly arise, but it could if the lawsuit had instead targeted Xanax’s manufacturer (Pfizer). If Pfizer knew that Xanax interacted dangerously with kratom and failed to warn patients about it, Pfizer could face liability. However, kratom is an unregulated supplement not approved by the FDA, which creates a gap in the pharmaceutical company’s knowledge—Pfizer cannot monitor every herbal supplement in existence or warn about every possible interaction. This gap highlights a fundamental limitation: pharmaceutical companies can only warn about interactions they know about, and the universe of drug combinations is vast and constantly expanding.
THE FUTURE OF DRUG INTERACTION LIABILITY IN THE AI AGE
The OpenAI ChatGPT lawsuit signals a significant shift in how drug interaction liability may evolve. As more people consult AI systems for health advice, and as these systems become more sophisticated, courts will grapple with whether AI companies bear the same duty of care as pharmacists or physicians. The case also raises questions about how AI systems should be designed to prevent dangerous medical misinformation.
Should ChatGPT refuse all medical questions and direct users to physicians? Should it include prominent disclaimers about its limitations? Should it maintain access to a real-time drug interaction database to verify its claims before responding? Future drug interaction lawsuits will likely involve increasingly complex fact patterns involving digital health tools, patient data systems, and AI. A patient might consult an AI chatbot, receive wrong advice, consult a pharmacist who relies on an electronic health record system that has not been updated with recent supplements the patient is taking, and then suffer harm when both the AI and the pharmacy fail. Determining liability in such cases will require understanding how multiple systems interact and fail. Courts will also face questions about foreseeability and causation—should AI companies be held responsible for every harmful health outcome a user experiences after consulting ChatGPT, or only for outcomes directly caused by specific false statements the AI made?.
Conclusion
Drug interaction lawsuits represent an evolving category of pharmaceutical and personal injury litigation that addresses harm caused when multiple medications or substances interact dangerously in the human body. These cases can target pharmaceutical companies for inadequate warnings, pharmacies for failure to screen for interactions, doctors for negligent prescribing, AI systems for dangerous health misinformation, and supplement companies for lack of safety information. The most prominent recent example—the lawsuit by Texas parents against OpenAI following their son’s death from a kratom-Xanax interaction recommended by ChatGPT—demonstrates that drug interaction liability is expanding into new domains as technology plays an increasing role in healthcare decision-making.
If you or a family member has been harmed by a dangerous drug interaction caused by negligence, prescription error, insufficient warnings, or bad advice from a healthcare provider or technology company, you may have a legal claim. An attorney specializing in pharmaceutical litigation can evaluate whether you have a case, identify the responsible parties, and advise you on pursuing compensation for medical expenses, lost wages, pain and suffering, and in wrongful death cases, punitive damages. Many attorneys work on contingency, meaning they collect payment only if you win your case, making it possible to pursue justice without upfront legal fees.
Frequently Asked Questions
What is the difference between a drug interaction and a drug side effect?
A drug side effect is an unwanted reaction that occurs when taking a single drug as prescribed, such as drowsiness from a sleeping pill or nausea from an antibiotic. A drug interaction occurs when two or more substances interact with each other in the body, producing effects that would not occur from either substance alone or producing more severe effects than either would cause independently.
Can I sue a pharmaceutical company if I was harmed by a drug interaction with one of their drugs?
You may be able to sue if the company failed to warn you or healthcare providers about a known dangerous interaction, or if the company knew about an interaction but did not disclose it adequately. You would need expert testimony showing that the interaction was foreseeable, that reasonable pharmaceutical companies warn about it, and that the company’s failure to warn directly caused your harm.
Is OpenAI likely to be held liable for Sam Nelson’s death?
The case is ongoing, so no final determination has been made. The outcome will depend on whether a court decides that OpenAI owed a duty of care to users asking health questions, whether ChatGPT’s advice was negligent, and whether there is causation between the advice and the death. This case will likely establish important precedent for AI liability.
Should I consult ChatGPT or other AI systems about drug interactions?
While AI systems can provide general information, they should not be your primary source for advice about drug interactions, especially if you are taking multiple medications or considering combining supplements and prescription drugs. Always consult your doctor, pharmacist, or a call to the poison control center (1-800-222-1222 in the United States) before combining substances.
What should I do if I think a pharmacy made an error with my medications?
Contact the pharmacy immediately to report the error and ask to speak with the pharmacist. Document what happened, keep your original prescription and the medications you received, and follow up in writing with the pharmacy. If you were harmed, consult an attorney about a potential liability claim.
What is a pharmacy benefits manager and how do they affect drug interactions?
A pharmacy benefits manager (PBM) like Express Scripts is a middleman company that manages prescription drug benefits for insurance plans. They can indirectly affect drug interaction safety by making certain medications unaffordable, which may pressure patients to skip doses, switch to cheaper alternatives, or forgo necessary medications—all of which could increase drug interaction risks.